Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OASIS-2: Oral Omadacycline vs Linezolid in ABSSSI
NCT02877927Phase 3Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Aug 2016
- Primary completion
- May 2017
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of omadacycline in acute bacterial skin and skin structure infection (ABSSSI), sponsored by Paratek Pharmaceuticals. Started Aug 2016; status: completed.
02
Drugs
omadacycline
03
Conditions
acute bacterial skin and skin structure infection (ABSSSI)
Beyond the preview
Go deeper on NCT02877927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02877927.